Departmental Seminars

Every week on Monday, until 27th Nov 2017
12:30pm - 1:30pm

2017 Seminars - No RSVP required

Creating a research profile: why, when, and where?
Dr Rosemarie Boland, Postdoctoral Research Fellow
Murdoch Childrens Research Institute & The University of Melbourne
Monday 27 March, 12.30 pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital

Cartoon of 2 scientists discussing H-Index and dating

Rosemarie Boland is a neonatal nurse, midwife, perinatal educator and researcher. She is currently leading a 5-year program of postdoctoral research aimed at reducing mortality and morbidity in preterm infants born in non-tertiary hospitals in Victoria, funded by the Murdoch Childrens Research Institute.
Rose will talk about when, why and where to create a research profile, focusing on the importance of the research profile for an NHMRC grant application.

-------------------------------------

TBA
Kate Callanan
Premature Infant Follow Up Studies, The Royal Women's Hospital
Monday 10 April, 12.30 pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital

------------------------------------

TBA
Dr Thomas Cade
Department of Obstetrics & Gynaecology, The University of Melbourne
Monday 01 May, 12.30 pm, Seminar Rooms 7A/B, Level 7, The Royal Women’s Hospital

-------------------------------------

Vascular dysfunction in preeclampsia: an ex vivo approach to assess drugs
Sarah Marshall, Early Career Researcher
Monash University
Monday 08 May, 12.30 pm, Seminar Rooms 7D/E, Level 7, The Royal Women’s Hospital

Image of ex viv model of vascular dysfunctionA characteristic of preeclampsia (PE) is widespread maternal vascular dysfunction, often attributed to high circulating concentrations of anti-angiogenic factors sFlt-1 and sEng. In an attempt to replicate this dysfunction, an ex vivo model was established. Primary trophoblast cells were cultured for 24 hours to secrete large amounts of sFlt-1 and sEng, termed trophoblast conditioned media (TCM). Mouse arteries were exposed to TCM providing levels of sFlt-1 and sEng similar to those during PE to cause vascular dysfunction. This ex vivo model is now being utilized to assess the therapeutic ability of a variety of drugs to alleviate maternal systemic vascular dysfunction associated with PE.

------------------------------------